Dowty, Martin E <br/><br/>
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.  [electronic resource] 

 -  Pharmacology research & perspectives  12 2019 
 - e00537 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2052-1707 
<br/><br/><label>Standard No.: </label>10.1002/prp2.537  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antirheumatic Agents--pharmacology<br/>Arthritis, Rheumatoid--drug therapy<br/>Azetidines--pharmacology<br/>Cell Line<br/>Cytokines--metabolism<br/>Enzyme Assays<br/>Female<br/>Healthy Volunteers<br/>Heterocyclic Compounds, 3-Ring--pharmacology<br/>Humans<br/>Inhibitory Concentration 50<br/>Janus Kinase 1--antagonists & inhibitors<br/>Janus Kinase Inhibitors--pharmacology<br/>Male<br/>Piperidines--pharmacology<br/>Purines<br/>Pyrazoles<br/>Pyridines--pharmacology<br/>Pyrimidines--pharmacology<br/>Pyrroles--pharmacology<br/>Receptors, Cytokine--antagonists & inhibitors<br/>Sulfonamides--pharmacology<br/>Triazoles--pharmacology